Cibinetide
Also called ARA-290, EPO-derived 11-mer
Research reference
- Research amount range
- 1–8 mg per administration — not a starting amount
- Reference frequency
- Every day — catalogue input, not a personal schedule
- Evidence route
- Subcutaneous in the cited evidence; formulation matters. Sites and rotation
- Model accumulation timescale
- ~0 hours — about five half-lives with regular repeated exposure; not time to a result
- Storage
- Storage and in-use limits depend on the exact formulation and packaging. A compound name alone cannot establish temperature, diluent, or shelf life. Details
A research and community reference, not medical advice. Figures are descriptive, vary between sources, and are not a recommendation for use.
When results may show
Cibinetide
Evidence gap- When change was measured
- Human exposure or dose research exists for Cibinetide, but this catalogue has no source-backed window for a visible or functional result. Pharmacokinetic or biomarker timing is not the same as outcome timing.
- When to assess
- No evidence-based reassessment point is available for this catalogue entry. Half-life or clearance time cannot be used as a proxy for when a result should appear.
- Conditions and limitations
- No source-backed special condition—such as fasting, local injection, exercise timing, or a companion compound—has been established for the claimed outcomes. Route and formulation still matter.
- When to stop
- No validated target, maintenance phase, or quit rule is available. Do not extend or increase exposure solely because an expected result has not appeared; a severe or persistent reaction warrants stopping and prompt clinical review.
No direct outcome source identified. See the compound page for evidence grading.
Research timing is descriptive, not a promise or personal instruction. A severe or persistent reaction needs prompt clinical review. This is not medical advice.
Vial arithmetic
Published research contexts for Cibinetide describe 1–8 mg per administration. Descriptive only, not a recommendation.
Minutes-scale in plasma; the decay chart is largely illustrative here.
Research schedule reference
Reported schedule context for Cibinetide; not a plan to start or adjust personal use.
These are commonly-discussed research protocols shared for educational reference. Study amounts apply to the source's population, formulation, and oversight; they do not establish personal suitability. This is not medical advice and is not a substitute for guidance from a qualified professional.
| Phase | Amount | Frequency | Route |
|---|---|---|---|
| Studied daily doseThe amount carried through the 28-day study. | 4 mg | Once daily | SubQ |
| Range exploredSingle ascending doses of 1, 4 and 8 mg were assessed. | 1–8 mg | Once daily | SubQ |
Modelled level — every day
1× is the peak after a single dose.
- Steady-state peak
- 0.94× single dose
- Time to steady state
- 0hours
- Administrations
- 7/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- Dahan A et al., Mol Med 2013;19:334Subcutaneous cibinetide (ARA-290) 4 mg once daily for 28 days assessed in sarcoidosis-associated small-fibre neuropathy.
- Culver DA et al., 2017Subcutaneous cibinetide at 1, 4 and 8 mg once daily assessed over 28 days for corneal nerve-fibre measures.